Alkaline Phosphatase Anti-WDR4 antibody [EPR11052],Abcam,AB308867

How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .

Host

Rabbit

Reactivity

Human

Application

Target Binding Affinity, Antibody Labelling

Conjugate

Alkaline Phosphatase

Platform ID

BAB199048762

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAlkaline Phosphatase Anti-WDR4 antibody [EPR11052]
Cat. No.AB308867
HostRabbit
IsotypeIgG
ReactivityHuman
ConjugationAlkaline Phosphatase
ApplicationTarget Binding Affinity, Antibody Labelling
ClonalityMonoclonal
Clone NumberEPR11052
Concentration0.25 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.1% Proclin 300 Solution Constituents: 50% Glycerol (glycerin, glycerine), 1% BSA, 0.016% Magnesium chloride, 0.001% Zinc chloride
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Non-catalytic component of the METTL1-WDR4 methyltransferase complex required for the formation of N(7)-methylguanine in a subset of RNA species, such as tRNAs, mRNAs and microRNAs (miRNAs) (PubMed : 12403464, PubMed : 31031083, PubMed : 31031084, PubMed : 36599982, PubMed : 36599985, PubMed : 37369656). In the METTL1-WDR4 methyltransferase complex, WDR4 acts as a scaffold for tRNA-binding (PubMed : 36599982, PubMed : 36599985, PubMed : 37369656). Required for the formation of N(7)-methylguanine at position 46 (m7G46) in a large subset of tRNAs that contain the 5'-RAGGU-3' motif within the variable loop (PubMed : 12403464, PubMed : 34352206, PubMed : 34352207, PubMed : 36599982, PubMed : 36599985, PubMed : 37369656). M7G46 interacts with C13-G22 in the D-loop to stabilize tRNA tertiary structure and protect tRNAs from decay (PubMed : 36599982, PubMed : 36599985). Also required for the formation of N(7)-methylguanine at internal sites in a subset of mRNAs (PubMed : 31031084, PubMed : 37379838). Also required for methylation of a specific subset of miRNAs, such as let-7 (PubMed : 31031083). Independently of METTL1, also plays a role in genome stability : localizes at the DNA replication site and regulates endonucleolytic activities of FEN1 (PubMed : 26751069). See full target information WDR4

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.